Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse for at vurdere effektiviteten af ​​BOTOX (Botulinum Toxin Type A)-injektioner til ændring af Masseter-muskelprominens hos voksne deltagere (MMP EU P3)

13. november 2026 opdateret af: AbbVie

BOTOX® (Botulinum Toxin Type A) til reduktion af Masseter Muscle Prominence: En fase 3, multicenter, randomiseret, dobbeltblind, placebokontrolleret undersøgelse

The masseter muscle is one of the muscles in the lower face used for chewing. Prominence of the masseter muscle can appear as a widened and square lower face shape, which is an aesthetic concern for individuals who prefer a narrower and more ovoid lower face shape. Treatments are available for masseter muscle prominice (MMP), but researchers are looking for new non-surgical treatments. This study will assess adverse events and effectiveness of BOTOX in adult participants with MMP.

BOTOX is being investigated for the treatment of MMP. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is 1 in 4 chance that participants will be assigned to placebo. Around 248 adult participants with MMP will be enrolled in the study at approximately 30 sites in Europe.

Participants will receive either BOTOX or Placebo administered as 6 intramuscular injections to the masseter on Day 1. Participants who are eligible for retreatment will be given BOTOX on Day 180 and will be followed for up to 6 months.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

249

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Antwerpen
      • Beerse, Antwerpen, Belgien, 2340
        • Da Vinci Clinic /ID# 246731
      • Schilde, Antwerpen, Belgien, 2970
        • Evolve Clinic /ID# 246729
    • Brussels Capital
      • Jette, Brussels Capital, Belgien, 1090
        • Universitair Ziekenhuis Brussel /ID# 246311
    • Oost-Vlaanderen
      • Melle, Oost-Vlaanderen, Belgien, 9090
        • Lightfalls Clinic /ID# 247335
      • Plovdiv, Bulgarien, 4000
        • Dermavist - Group Practice for Specialized Medical Care for Skin Disease /ID# 247630
      • Sofia, Bulgarien, 1700
        • Medical Centre Dermatology Dr. Denkova EOOD /ID# 246591
      • Sofia, Bulgarien, 1407
        • Medical Center Derma Vita EOOD /ID# 247327
      • Edinburgh, Det Forenede Kongerige, EH3 6RS
        • Dr Nestor's Medical Cosmetic Centre /ID# 246437
      • London, Det Forenede Kongerige, W1H 6AZ
        • Interface Aesthetics Training Limited /ID# 248115
      • Sutton Coldfield, Det Forenede Kongerige, B74 2UG
        • MediZen /ID# 246431
    • North Lanarkshire
      • Coatbridge, North Lanarkshire, Det Forenede Kongerige, ML5 3AP
        • Waverley Medical Practice /ID# 246432
      • Antibes, Frankrig, 06160
        • Mediti /Id# 246875
      • Cannes, Frankrig, 06400
        • Cabinet Dermatologie et Esthetique /ID# 246871
      • Paris, Frankrig, 75007
        • Cabinet médical /ID# 246873
      • Toulouse, Frankrig, 31000
        • Cabinet de Chirurgie Plastique et Esthétique /ID# 246872
      • Latina, Italien, 04100
        • Azienda Unita Sanitaria Locale Latina /ID# 246835
      • Roma, Italien, 00128
        • Fondazione Policlinico Universitario Campus Bio-Medico /ID# 246836
      • Verona, Italien, 37134
        • CRC - Centro Ricerche Cliniche di Verona S.r.l. /ID# 246834
      • Madrid, Spanien, 28006
        • Grupo Pedro Jaen /ID# 246485
      • Madrid, Spanien, 28008
        • Clinica Robega /ID# 252239
    • Pontevedra
      • Vigo, Pontevedra, Spanien, 36201
        • Gavín Dermatólogos /ID# 252120
    • Valencia
      • Valencia, Valencia, Spanien, 46004
        • Clinica Alejandria /ID# 247380
      • Hamburg, Tyskland, 20146
        • Universitaet Hamburg /ID# 247503
    • Bavaria
      • Munich, Bavaria, Tyskland, 80333
        • Hautok and Hautok-cosmetics /ID# 246600
      • Munich, Bavaria, Tyskland, 80333
        • Studienzentrum Theatiner46 /ID# 246601
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Tyskland, 50996
        • Hautzentrum Koeln /ID# 247502
      • Düsseldorf, North Rhine-Westphalia, Tyskland, 40212
        • Privatpraxis Dr. Hilton & Partner /ID# 246602

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Body mass index < 30 kg/m^2 using the calculation: BMI = weight (kg)/height (m)^2, rounded to the nearest whole number.

  • Participants meets the following criteria:

    • Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right side of the face), as determined at screening and at the Day 1 visit by the investigator using the MMPS.
    • Bilateral Grade 4 or Grade 5 MMP (identical grades for left and right sides of the face), as determined at the Day 1 visit by the participant using the MMPS-P.
    • MMP grades, as assessed by investigator and participant, do not need to be identical but have to be a minimum of Grade 4 with bilateral symmetry at Day 1.
  • Participants who responded "A lot" or "Extremely" bothered by the appearance of their MMP as measured by the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP) and attain a total score of ≥ 15 on the Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA), determined at the Day 1 visit.

Exclusion Criteria:

  • Has current intraoral infection, including infection of the mouth or gums, or facial skin infection requiring medical treatment in the opinion of the investigator.
  • Has weakness of the masseter, pterygoid, or temporalis muscles due to trauma, facial nerve injury, or other condition that could interfere with normal chewing and jaw clenching, as determined by the investigator.
  • Excess lower facial fat, jowling, loose or lax skin in lower face, or parotid gland prominence that could interfere with MMPS or MMPS-P grading, as determined by the investigator.
  • Has medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function.
  • History of dental or surgical procedure for lower facial shaping or masseter muscle reduction.
  • History of any soft tissue fillers in the jawline.
  • Has prior exposure to botulinum toxin of any serotype to any part of the body (not including masseter muscle) within the 3 months prior to Day 1.
  • History of or current TMJD, or presence of signs/symptoms of possible TMJD in the opinion of the investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Sekventiel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Double-Blind Period: Botox

Participants will receive 6 intramuscular injections of BOTOX to the masseter on Day 1.

Intramuscular Injections

Andre navne:
  • Botulinumtoksin type A
Eksperimentel: Open-Label Period: Botox

Participants who are eligible for retreatment will be given open-label BOTOX on Day 180 and will be followed for up to 6 months

Intramuscular Injections

Andre navne:
  • Botulinumtoksin type A
Placebo komparator: Double Blind Period: Placebo

Participants will receive 6 intramuscular injections of Placebo to the masseter on Day 1.

Intramuscular Injections

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale (MMPS) as assessed by the Investigator
Tidsramme: Day 90

The investigator assessed the severity of the participant's MMP using the MMPS 5-point scale where: 1=minimal (best), 2=mild, 3=moderate, 4=marked, and 5=very marked (worst).

Day 90
Achievement of 2-grade or more improvement from baseline on the Masseter Muscle Prominence Scale - Participant (MMPS-P) as assessed by the Participant
Tidsramme: Day 90

The participant assessed the severity of their MMP using the MMPS-P 5-point scale where: 1=not at all pronounced (best), 2=mildly pronounced, 3=moderately pronounced, 4=pronounced, and 5=very pronounced (worst).

Day 90

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Response of "Very Satisfied" or "Satisfied" on the Lower Facial Shape Questionnaire - Treatment Satisfaction Assessment (LFSQ-TXSAT)
Tidsramme: Day 90 to Day 180

The LFSQ-TXSAT measures the participant's satisfaction with the effect of treatment on the appearance of their lower face where 2=Very satisfied, 1=Satisfied, 0=Neither satisfied nor dissatisfied, -1=Dissatisfied, -2=Very dissatisfied.

Day 90 to Day 180
Response of "Not at all bothered" or "A little bothered" on the Bother Impact Assessment for Masseter Muscle Prominence (BIA-MMP)
Tidsramme: Day 90 to Day 180

The BIA-MMP is a single item evaluation of how bothered the participant is by the appearance of their lower face where 0=Not at all bothered, 1=A little bothered, 2=Somewhat bothered, 3=A lot bothered, 4=Extremely bothered.

Day 90 to Day 180
Change from baseline in lower facial volume (cm^3)
Tidsramme: Day 90

Lower facial volume is calculated from standardized images

Day 90
Change from baseline in lower facial width (mm)
Tidsramme: Day 90

Lower facial width is calculated from standardized images

Day 90
Change from baseline in Lower Facial Shape Questionnaire - Impact Assessment (LFSQ-IA) summary score
Tidsramme: Day 90 to Day 180

The LFSQ-IA is a 6-item assessment that measures psychosocial impact of the appearance of the lower face where 0= Not at all, 1=A little bit, 2=Somewhat, 3=Quite a bit and 4=Extremely.

Day 90 to Day 180

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: ABBVIE INC., AbbVie

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

17. oktober 2023

Primær færdiggørelse (Faktiske)

20. november 2025

Studieafslutning (Faktiske)

20. november 2025

Datoer for studieregistrering

Først indsendt

29. september 2023

Først indsendt, der opfyldte QC-kriterier

29. september 2023

Først opslået (Faktiske)

5. oktober 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

17. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • M23-123
  • 2022-500568-37-00 (Anden identifikator: EU CT)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

IPD-delingsadgangskriterier

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .